Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 OVERALL
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
A multicenter, prospective, randomized and controlled study to compare the efficacy and
safety of obinutuzumab and rituximab in adult ALL patients with CD20 expression.Study
population is 124 patients (62 in each study group).
Phase:
Phase 2
Details
Lead Sponsor:
Maria Sklodowska-Curie Institute - Oncology Center